AEGR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AEGR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aegerion Pharmaceuticals's interest expense for the three months ended in Sep. 2016 was $ -7.7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2016 was $-28.9 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aegerion Pharmaceuticals's Operating Income for the three months ended in Sep. 2016 was $ -18.8 Mil. Aegerion Pharmaceuticals's Interest Expense for the three months ended in Sep. 2016 was $ -7.7 Mil. Aegerion Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Aegerion Pharmaceuticals's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aegerion Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec05 | Dec06 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | -1.11 | -0.94 | -0.72 | -9.94 | -27.61 |
Aegerion Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | |
Interest Expense | Get a 7-Day Free Trial | -7.11 | -6.49 | -7.20 | -7.45 | -7.72 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aegerion Pharmaceuticals (NAS:AEGR) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Aegerion Pharmaceuticals's Interest Expense for the three months ended in Sep. 2016 was $-7.7 Mil. Its Operating Income for the three months ended in Sep. 2016 was $-18.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2016 was $246.4 Mil.
Aegerion Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2016 is calculated as
Aegerion Pharmaceuticals did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Anne Vanlent | director | C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540 |
Benjamin Harshbarger | officer: General Counsel and Secretary | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Sandford D Smith | director | C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Gregory D Perry | other: See Remarks | C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451 |
Gotto Antonio M Jr Md D Phil | director | MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604 |
Jorge Md Plutzky | director | C/O VIVUS, INC. 1172 CASTRO STREET MOUNTAIN VIEW CA 94040 |
Paul Thomas | director | ONE MILLENNIUM WAY, BRANCHBURG NJ 08876 |
Sol J Barer | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Mary T Szela | director, officer: Chief Executive Officer | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
John J Orloff | officer: EVP, Research and Development | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Martha J. Carter | officer: See Remarks | C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960 |
Eric Curtis | officer: President, U.S. Commercial | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
From GuruFocus
By Dividend Dividend • 12-27-2012
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.